Concord Wealth Partners Lineage Cell Therapeutics, Inc. Transaction History
Concord Wealth Partners
- $603 Million
- Q4 2024
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
132Shares Held
92.6MCall Options Held
80.9KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$28.7 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$5.96 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$4.99 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$4.11 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $117M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...